PubRank

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Clinical Trial ID NCT00858871

PubWeight™ 29.51‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00858871

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013 3.45
2 Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011 2.85
3 HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011 2.10
4 The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2010 2.07
5 Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med 2012 1.71
6 Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2012 1.57
7 Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012 1.55
8 Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012 1.20
9 Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol 2014 1.17
10 Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol 2013 1.05
11 Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol 2015 1.05
12 Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gastroenterol 2013 1.02
13 Targeting fibroblast growth factor pathways in prostate cancer. Clin Cancer Res 2013 0.98
14 Antiangiogenic therapies for advanced hepatocellular carcinoma. Oncologist 2013 0.94
15 Targeting the tumor stroma in hepatocellular carcinoma. World J Hepatol 2015 0.86
16 Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget 2010 0.84
17 Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol 2016 0.83
18 Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol 2013 0.83
19 Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. BMC Cancer 2010 0.79
20 Systemic therapy in hepatocellular carcinoma. Clin Liver Dis 2011 0.78
21 Accomplishments in 2008 in the management of hepatobiliary cancers. Gastrointest Cancer Res 2009 0.76
22 Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. Front Pharmacol 2016 0.75
23 Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2010 0.75
24 Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma. J Hepatocell Carcinoma 2014 0.75
Next 100